Navigation Links
Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
Date:8/4/2009

w.poniard.com. A replay of the Webcast will be available on the Company's Web site for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information, please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements, including statements regarding the Company's financial position and results of operations, business objectives and strategic goals, drug development plans, the potential safety and efficacy of its products in development, and commercialization and partnering strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of th
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
2. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
3. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
4. Poniard Pharmaceuticals Files Shelf Registration
5. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
6. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
7. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
8. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
9. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
10. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
11. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... Canada Endoscopy Visualization Systems Market Outlook ... Canada Endoscopy Visualization Systems market. The report provides ... units) and average prices (in US dollars) within ... Endoscopy Visualization Systems and Low-End Endoscopy Visualization Systems. ... , The report also provides company shares and ...
(Date:7/25/2014)... NY (PRWEB) July 26, 2014 ... Review, H2, 2014" provides data on the Ischemic ... report provides elemental information and data relating to ... Stroke. , View full global Ischemic Stroke Research ... includes an overview of the trial numbers and ...
(Date:7/25/2014)... Amgen (NASDAQ: AMGN ) announced ... per share dividend for the third quarter of 2014. ... to all stockholders of record as of the close ... About Amgen Amgen is committed to unlocking the potential ... discovering, developing, manufacturing and delivering innovative human therapeutics. This ...
(Date:7/25/2014)... of bacteria live in each person,s digestive tract. Scientists ... and stave off harmful infections, but their role in ... shed light on the role of these bacteria, a ... Alm recently tracked fluctuations in the bacterial populations of ... described in the July 25 issue of the journal ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... , SAN MATEO, Calif., Nov. 6 , ... of Qutenza(TM) E.U. Marketing Authorization to Astellas Pharma Europe Ltd. ... Expanded management team to include VP Sales; Senior Director, Marketing; ... board as director and Audit Committee chairman , ...
... Therapeutics, Inc. delivered two presentations today on its ITCA ... treatment of type 2 diabetes at the Ninth Annual ... http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) , Continuous Subcutaneous Delivery ... and Reduces Weight in a 28-day Phase 1b Study ...
... Md., Nov. 5 GenVec, Inc. (Nasdaq: GNVC ) today ... 2009. GenVec reported a net loss of $3.6 million ($0.04 per ... a net loss of $6.8 million ($0.08 per share) in the ... 2009, GenVec,s net loss was $14.1 million ($0.15 per share), compared ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
(Date:7/25/2014)... the first broad-scale estimate of air pollution removal by ... that trees are saving more than 850 human lives ... symptoms. , While trees, pollution removal equated to an ... the impacts of that improvement are substantial. Researchers valued ... at nearly $7 billion every year in a study ...
(Date:7/25/2014)... on the land now called California, and many of ... plants they used for food, fuel, tools, and ritual. ... habitat and natural resources. , Frank Lake, an ecologist ... lead a field trip to the Stone ... America,s 99th Annual Meeting, in Sacramento, Cal. this August. ...
(Date:7/25/2014)... false-color image from the Terra satellite show the different areas ... in Eastern Russia. The burn scars show up as ... wildfires have broken across the remote parts of Eastern Russia ... from the MODIS instrument, it is still possible to ... recent image features noted below show the devastating number of ...
Breaking Biology News(10 mins):First national study finds trees saving lives, reducing respiratory problems 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... on the tap to get a glass of water, we just ... really safe? And, what exactly is "safe"? The public ... Marylynn Yates , a professor of environmental microbiology at the University ... will help the audience become familiar with the most common causes ...
... and clean people,s water supplies while serving as important ... cranes and alligators. Conventional ecosystem health assessments have focused ... unseen creatures in the wetlands provided crucial indicators of ... Missouri Associate Professor of Engineering Zhiqiang Hu and his ...
... GSA Bulletin articles posted online ahead of ... in central Asia; (2) crystal xenoliths in the Bolivian Altiplano; ... Group contact, Barberton greenstone belt, South Africa; (5) iron oxide ... Alaska syntaxis; (7) paleotopography of the South Norwegian margin; and ...
Cached Biology News:How safe is our drinking water? 2Measuring microbes makes wetland health monitoring more affordable, says MU researcher 2Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 2Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 3Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 4Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 5Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 6Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 7Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 8Contacts, collisions, sutures, belts, and margins -- new GSA Bulletin content 9
...
... Vacuum pumps deliver critical performance for all ... control optimizes pump performance to suit all ... for convenient checking of proper oil levels ... pumps is designed to work with all ...
... The IITC Life Science Rotarods are used ... motor coordination or fatigue resistance on mice and ... humane way. Extremely user friendly; the animals are ... an animal drops onto the individual sensing platforms ...
... Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) is a ... PGF2α), in rabbits, monkeys and humans. ... of non-specific lipid peroxidation. In both ... is converted primarily to metabolites having ...
Biology Products: